KalVista Pharmaceuticals, Inc. (KALV) financial statements (2021 and earlier)
Company profile
| Business Address |
55 CAMBRIDGE PARKWAY CAMBRIDGE, MA 02142 |
| State of Incorp. | DE |
| Fiscal Year End | April 30 |
| SIC | 2834 - Pharmaceutical Preparations (benchmarking) |
| More info | Complete financial analysis Financial benchmarking |
Balance sheet (Statement of financial position) ($ in millions)
| 1/31/2020 TTM | 4/30/2019 | 4/30/2018 | 4/30/2017 | 12/31/2015 | |||
|---|---|---|---|---|---|---|---|
| ASSETS | |||||||
| Current Assets | |||||||
| Cash, cash equivalents, and short-term investments | 81 | 101 | 51 | 31 | 54 | ||
| Cash and cash equivalents | 19 | 32 | 51 | 31 | 54 | ||
| Short-term investments | 62 | 69 | |||||
| Receivables | 7 | 3 | |||||
| Other undisclosed current assets | 18 | 15 | 1 | 1 | 1 | ||
| Total current assets: | 99 | 116 | 59 | 34 | 55 | ||
| Noncurrent Assets | |||||||
| Operating lease, right-of-use asset | 1 | ✕ | ✕ | ✕ | ✕ | ||
| Property, plant and equipment | 2 | 2 | 2 | 0 | 1 | ||
| Restricted cash and investments | 0 | ||||||
| Other noncurrent assets | 0 | 0 | 0 | 1 | |||
| Total noncurrent assets: | 4 | 3 | 2 | 0 | 2 | ||
| TOTAL ASSETS: | 103 | 118 | 61 | 34 | 57 | ||
| LIABILITIES AND EQUITY | |||||||
| Liabilities | |||||||
| Current Liabilities | |||||||
| Accounts payable and accrued liabilities | 8 | 8 | 5 | 3 | 3 | ||
| Accounts payable | 3 | 3 | 1 | 1 | 1 | ||
| Accrued liabilities | 5 | 6 | 3 | 2 | 1 | ||
| Deferred revenue | 1 | ✕ | ✕ | ✕ | ✕ | ||
| Debt | 1 | 0 | 0 | 1 | |||
| Deferred revenue and credits | ✕ | ✕ | 0 | ||||
| Contract with customer, liability | ✕ | 10 | ✕ | ✕ | ✕ | ||
| Other undisclosed current liabilities | 18 | ||||||
| Total current liabilities: | 10 | 18 | 23 | 3 | 4 | ||
| Noncurrent Liabilities | |||||||
| Long-term debt and lease obligation | 1 | 0 | 3 | ||||
| Long-term debt, excluding current maturities | 3 | ||||||
| Capital lease obligations | ✕ | 0 | |||||
| Operating lease, liability | 1 | ✕ | ✕ | ✕ | ✕ | ||
| Liabilities, other than long-term debt | 3 | 3 | 0 | ||||
| Deferred revenue and credits | ✕ | ✕ | 0 | ||||
| Deferred revenue | 3 | ✕ | ✕ | ✕ | ✕ | ||
| Contract with customer, liability | ✕ | 3 | ✕ | ✕ | ✕ | ||
| Other undisclosed noncurrent liabilities | 11 | ||||||
| Total noncurrent liabilities: | 3 | 3 | 11 | 3 | |||
| Total liabilities: | 13 | 21 | 34 | 3 | 7 | ||
| Stockholders' equity | |||||||
| Stockholders' equity attributable to parent | 90 | 97 | 27 | 31 | 49 | ||
| Common stock | 0 | 0 | 0 | 0 | 0 | ||
| Additional paid in capital | 206 | 191 | 100 | 90 | 122 | ||
| Accumulated other comprehensive loss | (1) | (2) | (1) | (3) | |||
| Accumulated deficit | (115) | (92) | (72) | (56) | (73) | ||
| Total stockholders' equity: | 90 | 97 | 27 | 31 | 49 | ||
| TOTAL LIABILITIES AND EQUITY: | 103 | 118 | 61 | 34 | 57 | ||
Income statement (P&L) ($ in millions)
| 1/31/2020 TTM | 4/30/2019 | 4/30/2018 | 4/30/2017 | 12/31/2015 | ||
|---|---|---|---|---|---|---|
| Revenue, net | ✕ | ✕ | 2 | 0 | ||
| Gross profit: | 12 | 16 | 8 | 2 | 0 | |
| Operating expenses | (55) | (46) | (27) | (24) | (21) | |
| Operating loss: | (43) | (30) | (19) | (22) | (21) | |
| Nonoperating income (expense) | 12 | 9 | 3 | 4 | (4) | |
| Investment income, nonoperating | 2 | 1 | 0 | 0 | 0 | |
| Foreign currency transaction gain (loss), before tax | 0 | 0 | (2) | 1 | ||
| Other nonoperating income | 10 | 8 | 4 | 2 | 1 | |
| Interest and debt expense | (3) | |||||
| Loss from continuing operations before income taxes: | (31) | (21) | (16) | (19) | (28) | |
| Income tax expense | (0) | |||||
| Other undisclosed loss from continuing operations | (0) | |||||
| Net loss: | (31) | (21) | (16) | (19) | (28) | |
| Other undisclosed net income attributable to parent | 3 | |||||
| Net loss available to common stockholders, diluted: | (31) | (21) | (16) | (19) | (25) | |
Comprehensive Income ($ in millions)
| 1/31/2020 TTM | 4/30/2019 | 4/30/2018 | 4/30/2017 | 12/31/2015 | ||
|---|---|---|---|---|---|---|
| Net loss: | (31) | (21) | (16) | (19) | (28) | |
| Other comprehensive income | 1 | |||||
| Other undisclosed comprehensive income | 1 | |||||
| Comprehensive loss: | (30) | (21) | (16) | (19) | (28) | |
| Other undisclosed comprehensive income (loss), net of tax, attributable to parent | (1) | (1) | 2 | (3) | ||
| Comprehensive loss, net of tax, attributable to parent: | (30) | (22) | (14) | (21) | (28) | |
Statements sources
The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.